Centessa Pharmaceuticals (CNTA) Equity Ratio (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Equity Ratio data on file, last reported at 0.76 in Q1 2026.

• Quarterly Equity Ratio rose 3.78% year-over-year to 0.76 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.76 (up 3.78% YoY) and the FY2025 annual result came in at 0.77, up 10.08% from the prior year.
• Equity Ratio slipped to 0.76 in Q1 2026 per CNTA's latest filing, from 0.77 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.82 in Q1 2022 and bottomed at 0.66 in Q1 2024.
• The 5-year median for Equity Ratio is 0.73 (2023), against an average of 0.73.
• The widest annual swing landed in 2024, when Equity Ratio gained 19.1%; it then retreated 17.83% in 2025.
• Tracing CNTA's Equity Ratio over 5 years: stood at 0.76 in 2022, then declined by 13.33% to 0.66 in 2023, then grew by 6.16% to 0.7 in 2024, then grew by 10.08% to 0.77 in 2025, then declined by 0.91% to 0.76 in 2026.
• Per Business Quant, the three latest CNTA Equity Ratio figures stand at 0.76 (Q1 2026), 0.77 (Q4 2025), and 0.67 (Q3 2025).

Peer Comparison